Cargando…
P74. A Good Manufacturing Practice procedure to generate therapeutic numbers of highly pure anti-leukaemic virus-specific T-cells
Autores principales: | van Loenen, MM, de Boer, R, van Liempt, E, Hagedoorn, RS, Meij, P, Jedema, I, Falkenburg, JHF, Heemskerk, MHM |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072150/ http://dx.doi.org/10.1186/2051-1426-2-S2-P48 |
Ejemplares similares
-
HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study
por: van Balen, Peter, et al.
Publicado: (2020) -
S78. Proffered paper: High-affinity CD20-specific TCRs suitable for adoptive immunotherapy can be readily isolated from the allo-repertoire using reverse immunology
por: Jahn, L, et al.
Publicado: (2014) -
Extracellular Domains of CD8α and CD8ß Subunits Are Sufficient for HLA Class I Restricted Helper Functions of TCR-Engineered CD4(+) T Cells
por: van Loenen, Marleen M., et al.
Publicado: (2013) -
Pseudo-Leukæmic Lymphosarcoma
por: Ainley, Norman J.
Publicado: (1949) -
Different distribution of adriamycin in normal and leukaemic rats.
por: Sonneveld, P., et al.
Publicado: (1981)